on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with biological medicines under the National Health Act 1953, section 85 and section 100 for patients with severe chronic plaque psoriasis.
Where the term biological medicine appears, it refers to:
- adalimumab
- bimekizumab
- etanercept
- guselkumab
- infliximab
- ixekizumab
- risankizumab
- secukinumab
- tildrakizumab
- ustekinumab.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing biological medicines.
Section 100 arrangements
Infliximab i.v.
This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public hospital.
This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.
Treatment specifics
To be eligible for PBS-subsidised treatment with biological medicines, patients must be treated by a dermatologist.
PASI calculation forms
PASI calculation and body diagram - whole body form
PASI calculation and body diagram - face, hand and foot form
Authority applications
Patients 18 years of age or older
Applying for initial treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial authority approval to prescribe PBS-subsidised biological medicines to treat severe chronic plaque psoriasis can be made:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed severe chronic plaque psoriasis - initial authority application form
- relevant attachments.
Applying for change or recommencement of treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications to change or recommence authority approval to prescribe PBS-subsidised biological medicines to treat adult patients with severe chronic plaque psoriasis can be made:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed severe chronic plaque psoriasis - change or recommencement authority application form
- relevant attachments.
Applying for continuing treatment
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Applications for continuing authority approval to prescribe PBS-subsidised biological medicines to treat adult patients with severe chronic plaque psoriasis can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed severe chronic plaque psoriasis - continuing authority application form
- relevant attachments.
After we approve the first application for continuing treatment, subsequent continuing treatments with PBS-subsidised biosimilar brands of biological medicines are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.
Patients under 18 years
Adalimumab and ustekinumab
Applying for initial, change or recommencement of treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial, change or recommencement authority approval to prescribe PBS-subsidised adalimumab or ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis can be made:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed severe chronic plaque psoriasis paediatric - adalimumab or ustekinumab - initial, change or recommencement authority application form
- relevant attachments.
Applying for continuing treatment
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Applications for continuing authority approval to prescribe PBS-subsidised adalimumab or ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis can be made in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed severe chronic plaque psoriasis paediatric - adalimumab or ustekinumab - continuing authority application form
- relevant attachments.
After we approve the first application for continuing treatment, subsequent continuing treatments with PBS-subsidised adalimumab or biosimilar brand of ustekinumab are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.
Etanercept
Applications for initial, change, recommencement, or re-treatment authority approval to prescribe PBS-subsidised etanercept to treat patients under 18 years with severe chronic plaque psoriasis can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Completion of the course of PBS-subsidised treatment with etanercept is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.